ArticleTranslational cancer research2025
Analysis and exploration of regulatory mechanisms and potential prognostic biomarkers in squamous cell carcinoma of the lung by expression profiling.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pan-cancer and single-cell analysis identifies MAGI2-AS3 as an immune regulator and prognostic biomarker with a focus on colorectal cancer.Discover oncology · 2026Article
- Long Non-coding RNAs in Non-small Cell Lung Carcinoma: Regulatory Mechanisms, Diagnostic Potential, and Therapeutic Perspectives.Current drug targets · 2026Review
- The changes of CD47 and PD-L1 (SP142) before and after neoadjuvant therapy help predict prognosis of patients with stage IIIA-N2 non-small cell lung cancer.International journal of clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the most common malignant tumor in China. In 2016, more than 800,000 new cases of lung cancer were diagnosed in China. Squamous cell carcinoma of the lung, a type of non-small cell lung cancer (NSCLC), accounts for 25-30% of all lung cancer cases, and has an overall 5-year survival rate of about 32.53%, lower than adenocarcinoma for which there have been far more therapeutic advances in the last few decades. The purpose of this study was to explore the mechanisms of the disease and to identify potential prognostic biomarkers. Methods: This study analyzed lung squamous cell carcinoma of the lung tissues and paraneoplastic tissues to identify differentially expressed genes (DEGs). We conducted a Gene Set Enrichment Analysis and prognostic analysis by constructing competing endogenous RNA (ceRNA) networks; we performed a correlation analysis of the target genes and verified the targeting relationship of the ceRNA by cellular assays. We assessed the effects of the target genes on tumor cell proliferation, invasion and apoptosis by Cell Counting Kit-8 (CCK-8) assays, invasion assays, and caspase 3/7 assays, respectively. Results: We identified 4,039 downregulated genes and 1,924 upregulated genes. The p53 pathway, cell-cycle pathway and mismatch-repair (MMR) pathway were activated, while the mitogen-activated protein kinase pathway was inhibited. Two ceRNA networks centered on the long non-coding RNAs (lncRNAs) MAGI2-AS3 and LINC01089 were constructed. Conclusions:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.